Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of ($1.25), $0.01 better than the analyst estimate of ($1.26).

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.